Loading
NASDAQHealthcareBiotechnology
Latest quote
$29.73
−$0.52 · -1.72%
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Previous close
$29.73
−$0.52 · -1.72%
After-hours
$29.73
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Day range
Current $29.73
52-week range
Current $29.73
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
33
Expensive
Sentiment
53
Mixed
Risk
50
Elevated Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Day range
Current $29.73
52-week range
Current $29.73
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | −846K USD | — |
| Gross profit | — | — | — | 846K USD | — |
| Research and development | 215.26M USD | 126.17M USD | 78.23M USD | 69.84M USD | 22.48M USD |
| Selling, general, and administrative | 100.22M USD | 41M USD | 23.79M USD | 21.91M USD | 11.92M USD |
| Operating expenses | 315.47M USD | 167.17M USD | 102.01M USD | 91.75M USD | 34.4M USD |
| Interest income | 24.48M USD | 20.71M USD | 7.98M USD | 1.75M USD | 15K USD |
| Interest expense | 7.53M USD | 7.63M USD | 3.79M USD | 992K USD | 20K USD |
| Depreciation and amortization | 468K USD | 105K USD | 21K USD | −846K USD | 176K USD |
| Operating income | −315.47M USD | −167.17M USD | −102.01M USD | −90.9M USD | −34.4M USD |
| Net income | −299.62M USD | −152.15M USD | −95.99M USD | −89.06M USD | −32.61M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
